Clinical trials: Severe Pneumonia
Coronavirus Disease 2019
Long-term COVID-19 Immune Response in a Vulnerable Neighbourhood in Argentina
Between June 10t h and July 1st, a cross-sectional design study in an Argentina slum, showed a prevalence based on immunoglobuling G-class (IgG) antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) of…
- Trial name
- NCT04673279
- Testing
- serology
- Where
- Argentina
- Volunteers
- 189 people
- Sponsor
- Hospital Italiano de Buenos Aires
Respiratory Syndrome, Acute, Severe, Hypoxic Respiratory Failure
Use of High Flow Nasal Cannula Oxygen and Covid-19 Acute Hypoxemic Respiratory Failure
Nasal High Flow oxygen therapy (NHF) is commonly used as first line ventilatory support in patients with acute hypoxemic respiratory failure (AHRF). It's use has been initially limited in Covid-19 patients presenting with AHRF.
- Conditions
- Respiratory Syndrome, Acute, Severe, Hypoxic Respiratory Failure, Viral Pneumonia
- Trial name
- NCT04385823
- Testing
- patients receiving nasal high flow
- Where
- France
- Volunteers
- 62 people
- Sponsor
- Hôpital Louis Mourier
Covid19, Kidney Diseases
Michigan Medicine COVID-19 Cohort: Clinical Characteristics, Inflammatory Markers and Outcomes of Patients Hospitalized for COVID-19
To better understand the role of inflammation in COVID-19, we established the Michigan Medicine COVID-19 Cohort (M2C2). M2C2 is a funded and ongoing cohort which has currently enrolled over 1500 adult patients (≥18 years) with…
- Conditions
- Covid19, Kidney Diseases, Inflammation, SARS-CoV Infection
- Trial name
- M2C2 (NCT04706533)
- Testing
- Biomarkers of inflammation
- Where
- United States
- Volunteers
- 3,402 people
- Sponsor
- University of Michigan
Influenza Infection, SAD-RV Infection and COVID-19
DAS181 for Patients With Severe Hospitalized Flu and SAD-RVs (COVID-19)
This is a Phase IIb study consisting of two cohorts to evaluate efficacy, safety and pharmacokinetics of DAS181 in IFV infection. An approximate total of 280 subjects will be enrolled into this study.
- Trial name
- STOP-Flu (NCT04298060)
- Testing
- DAS181
- Where
- China
- Volunteers
- 280 people
- Sponsor
- Ansun Biopharma, Inc.
COVID-19
A Clinical Trial of Convalescent Plasma Compared to Best Supportive Care for Treatment of Patients With Severe COVID-19
This is a randomized, prospective, multicenter, open label clinical trial of convalescent plasma compared to best supportive care for treatment of patients with severe COVID-19.
- Trial name
- CAPSID (NCT04433910)
- Testing
- Convalesscent Plasma
- Where
- 16 sites in Germany
- Volunteers
- 106 people
- Sponsor
- Deutsches Rotes Kreuz DRK-Blutspendedienst Baden-Wurttemberg-Hessen
COVID-19 Pneumonia
Lung Diffusing Capacity for Nitric Oxide and Carbon Monoxide Early After Mild-to-severe COVID-19
Infection with severe acute respiratory syndrome-CoV-2 (SARS-CoV-2) may be associated with diffuse alveolar damage and pulmonary vasculitis. Thus, it is likely that pulmonary function changes may be seen in COVID-19 survivors.
- Trial name
- NCT04610554
- Where
- Italy
- Volunteers
- 74 people
- Sponsor
- IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy
Covid19, COVID-19 Lower Respiratory Infection
In-patient COVID-19 Study of Intranasal Foralumab
This is a Phase 2, randomized, placebo-controlled, double-blind, proof-of-concept study of intranasal foralumab in hospitalized subjects with severe COVID-19 and pulmonary inflammation.
- Conditions
- Covid19, COVID-19 Lower Respiratory Infection, COVID-19 Respiratory Infection
- Trial name
- NCT04983446
- Testing
- Foralumab
- Sponsor
- Tiziana Life Sciences LTD
Covid19, Respiratory Disease
Home-based Respiratory Physiotherapy and Telephone-Based Psychological Support in Severe COVID-19 Patients
Some COVID-19 survivors may have respiratory and mental health sequelae, especially those who required hospitalization. The investigators hypothesize that the participation of a rehabilitation program composite by home-based…
- Conditions
- Covid19, Respiratory Disease, Mental Health Disorder
- Trial name
- WAYRA (NCT04649736)
- Testing
- Respiratory and psychological rehabilitation
- Where
- Peru
- Volunteers
- 108 people
- Sponsor
- Universidad Peruana Cayetano Heredia
SARS (Severe Acute Respiratory Syndrome), Covid19
Differences in Exhaled Breath by Using Ion Mobility Spectrometry (IMS) in Subjects Tested for SARS-CoV-2 Infection (COVID-19 Disease)
Breath gas analysis is the evaluation of exhaled breath. It aims to evaluate the volatile organic compounds (VOCs) in exhaled breath.
- Trial name
- NCT04649931
- Testing
- Ion Mobility Spectrometry (IMS)
- Where
- Germany
- Volunteers
- 450 people
- Sponsor
- B. Braun Melsungen AG
COVID-19
Incidence of COVID-19 Following Vaccination in Botswana Against SARS CoV 2
The AstraZeneca Study is a single-arm, open-label, interventional, Phase 3b study to determine the incidence of laboratory-confirmed COVID-19 hospitalizations, disease severity, and deaths and attributable adverse events (AEs) in…
- Trial name
- NCT05715944
- Testing
- AZD 1222
- Where
- Botswana
- Volunteers
- 10,888 people, healthy volunteers welcome
- Sponsor
- Botswana Harvard AIDS Institute Partnership
Pneumonia, Child
Predicting Severe Outcomes Among Children Hospitalized With Community-acquired Pneumonia
In this study, investigators aimed to develop and validate a risk score to predict severe outcomes (e.g., mortality and ICU admission) in children who were admitted to the Children's Hospital of Fudan University between 2017 and…
- Conditions
- Pneumonia, Child, Prognosis
- Trial name
- NCT05744609
- Testing
- exposures of interest: epidemiological data, clinical characteristics, laboratory data, and chest radiographic reports
- Where
- China
- Volunteers
- 6,000 people
- Sponsor
- Children's Hospital of Fudan University
Covid-19
Prophylactic Corticosteroid to Prevent COVID-19 Cytokine Storm
This is a Phase II pilot exploratory study designed to investigate if prophylactic treatment with short term steroids administered to high risk Covid-19 patient might prevent cytokine storm and progression to respiratory failure.
- Trial name
- NCT04355247
- Testing
- MethylPREDNISolone 80 Mg/mL Injectable Suspension
- Where
- 2 sites in Puerto Rico
- Volunteers
- 20 people
- Sponsor
- Auxilio Mutuo Cancer Center
SARS (Disease)
Cyclosporine For The Treatment Of COVID-19(+)
Phase IIa clinical trial in which 75 non-ICU hospital inpatients will be randomized 2:1 to 7 days of an oral formulation of cyclosporine, Neoral (2.5mg/kg PO BID) + standard of care (SOC) or no Neoral + SOC.
- Trial name
- NCT04492891
- Testing
- Cyclosporine, Standard of Care Treatment
- Where
- United States
- Volunteers
- 47 people, healthy volunteers welcome
- Sponsor
- Bryan Burt, MD
Pneumonia, Pneumocystis Carinii, HIV Infections
Randomized Phase I Study of Trimetrexate Glucuronate (TMTX) With Leucovorin (LCV) Protection Plus Dapsone Versus Trimethoprim / Sulfamethoxazole (TMP/SMX) for Treatment of Moderately Severe Episodes of Pneumocystis Carinii Pneumonia
To evaluate the safety of the combination of trimetrexate glucuronate (TMTX) and dapsone with leucovorin protection versus trimethoprim/sulfamethoxazole (TMP/SMX) in patients with AIDS and moderately severe Pneumocystis carinii…
- Trial name
- NCT00002120
- Testing
- Trimetrexate glucuronate, Trimethoprim, Sulfamethoxazole
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- U.S. Bioscience
COVID-19, SARS-CoV 2
Clinical Scores for Outcome Prediction in Patients With Severe COVID-19 Pneumonia Requiring ECMO
The prognosis of patients with severe COVID-19 disease, whose lungs are so severely diseased that they need to be supported by veno-venous ECMO (extracorporeal membrane oxygenation), is difficult to assess so far.
- Conditions
- COVID-19, SARS-CoV 2, Extracorporeal Membrane Oxygenation, ARDS
- Trial name
- NCT04405973
- Testing
- vv-ECMO
- Where
- Germany
- Volunteers
- 133 people
- Sponsor
- Dr. Alexander Supady
Corona Virus Infection, SARS (Severe Acute Respiratory Syndrome)
EFFICACY and SAFETY OF BEVACIZUMAB (ZIRABEV®) IN PATIENTS WITH SEVERE HYPOXEMIC COVID-19
Acute lung injury (ALI) and acute respiratory distress syndrome (ARDS) are the most frequent complications of the COVID-19 pandemic.
- Conditions
- Corona Virus Infection, SARS (Severe Acute Respiratory Syndrome), Virus Diseases, Coronaviridae Infections
- Trial name
- BEVA (NCT04822818)
- Testing
- BEVA+SOC, SOC
- Where
- France
- Volunteers
- 96 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Covid19, Respiratory Failure
Nebulised Heparin in Patients With Severe COVID-19
The Can nebulised HepArin Reduce morTality and time to Extubation in Patients with COVID-19 Requiring mechanical ventilation Meta-Trial (CHARTER-MT) is a prospective collaborative individual patient data analysis of randomised…
- Trial name
- CHARTER-MT (NCT04545541)
- Testing
- Nebulised unfractionated heparin (UFH)
- Where
- United States
- Volunteers
- 57 people
- Sponsor
- Australian National University
Coronavirus Disease (COVID-19), COVID-19
Retrospective Study on Severe Respiratory Illness to Access the Presence of COVID-19
Retrospective study from November 2019 -Febrauary 2020 on severe respiratory illness to access the presence or absence of COVID-19 in patients samples by real-time PcR
- Trial name
- Explore (NCT04346056)
- Where
- 2 sites in Egypt
- Volunteers
- 500 people
- Sponsor
- Ain Shams University
Covid19, ARDS
Treatment With Pirfenidone for COVID-19 Related Severe ARDS
A randomized, open label, two arm, pilot trial of Pirfenidone 2,403 mg administered per nasogastric tube or orally as 801mg TID for 4 weeks in addition to Standard of Care (SoC), compared to SoC alone, in a population of COVID-19…
- Trial name
- NCT04653831
- Testing
- Pirfenidone, Standard of care
- Where
- Israel
- Volunteers
- 26 people
- Sponsor
- Soroka University Medical Center
Covid19, SARS (Severe Acute Respiratory Syndrome)
Proxalutamide Treatment for Hospitalized COVID-19 Patients
The purpose of this study is to assess the efficacy and safety of Proxalutamide as a treatment for hospitalized COVID-19 male and female patients.
- Trial name
- NCT04728802
- Testing
- Proxalutamide
- Where
- 8 sites in Brazil
- Volunteers
- 645 people
- Sponsor
- Applied Biology, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.